Orexigen Therapeutics Company Profile (NASDAQ:OREX)

About Orexigen Therapeutics (NASDAQ:OREX)

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drug Manufacturers - Other
Sub-Industry: Biotechnology
Symbol: NASDAQ:OREX
CUSIP: 68616410
Web: www.orexigen.com

Capitalization:

Market Cap: $44.77 million
Outstanding Shares: 15,227,000

Average Prices:

50 Day Moving Avg: $3.04
200 Day Moving Avg: $3.17
52 Week Range: $1.65 - $6.49

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -0.57
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $47.82 million
Price / Sales: 0.94
Book Value: ($0.52) per share
Price / Book: -5.65

Profitability:

EBIDTA: ($157,570,000.00)
Net Margins: -71.59%
Return on Equity: -354.92%
Return on Assets: -29.11%

Debt:

Debt-to-Equity Ratio: 2.74%
Current Ratio: 4.17%
Quick Ratio: 3.81%

Misc:

Average Volume: 232,669 shs.
Beta: 2.72
Short Ratio: 10.41

Frequently Asked Questions for Orexigen Therapeutics (NASDAQ:OREX)

What is Orexigen Therapeutics' stock symbol?

Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."

How were Orexigen Therapeutics' earnings last quarter?

Orexigen Therapeutics, Inc. (NASDAQ:OREX) issued its earnings results on Tuesday, May, 9th. The company reported ($4.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.60) by $2.07. The firm earned $19.10 million during the quarter, compared to analysts' expectations of $20 million. Orexigen Therapeutics had a negative return on equity of 354.92% and a negative net margin of 71.59%. The firm's quarterly revenue was up 282.0% on a year-over-year basis. During the same period last year, the firm posted ($1.54) earnings per share. View Orexigen Therapeutics' Earnings History.

Who are some of Orexigen Therapeutics' key competitors?

Some companies that are related to Orexigen Therapeutics include Iradimed Corp (IRMD), CytoDyn (CYDY), Infinity Pharmaceuticals (INFI), AVEO Pharmaceuticals (AVEO), Adamis Pharmaceuticals Corp (ADMP), Microbot Medical (MBOT), Ophthotech Corp (OPHT), pSivida Corp. (PSDV), ArQule (ARQL), Mirati Therapeutics (MRTX), Digirad (DRAD), Edap Tms SA (EDAP), aTyr Pharma (LIFE), Galectin Therapeutics (GALT), BIOLASE (BIOL), Akari Therapeutics PLC (AKTX), Actinium Pharmaceuticals (ATNM) and Cellular Biomedicine Group (CBMG).

Who owns Orexigen Therapeutics stock?

Orexigen Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baupost Group LLC MA (14.62%), Foresite Capital Management II LLC (4.08%), Vanguard Group Inc. (3.69%), Foresite Capital Management III LLC (2.50%), NEA Management Company LLC (2.44%) and Credit Suisse AG (1.54%). View Institutional Ownership Trends for Orexigen Therapeutics.

Who sold Orexigen Therapeutics stock? Who is selling Orexigen Therapeutics stock?

Orexigen Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG and Goldman Sachs Group Inc.. View Insider Buying and Selling for Orexigen Therapeutics.

Who bought Orexigen Therapeutics stock? Who is buying Orexigen Therapeutics stock?

Orexigen Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Foresite Capital Management III LLC, EcoR1 Capital LLC, Foresite Capital Management II LLC, Wells Fargo & Company MN, KCG Holdings Inc., Morgan Stanley and Old West Investment Management LLC. View Insider Buying and Selling for Orexigen Therapeutics.

How do I buy Orexigen Therapeutics stock?

Shares of Orexigen Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Orexigen Therapeutics stock cost?

One share of Orexigen Therapeutics stock can currently be purchased for approximately $2.94.

Consensus Ratings for Orexigen Therapeutics (NASDAQ:OREX) (?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for Orexigen Therapeutics (NASDAQ:OREX)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
3/16/2016	Leerink Swann	Lower Price Target	Market Perform	$2.00 -> $1.00	N/A
3/16/2016	Piper Jaffray Companies	Downgrade	Overweight -> Neutral	$5.00 -> $2.00	N/A
3/16/2016	JMP Securities	Downgrade	Outperform -> Market Perform		N/A
2/29/2016	JPMorgan Chase & Co.	Downgrade	Overweight -> Neutral		N/A
2/29/2016	Royal Bank of Canada	Downgrade	Outperform -> Sector Perform	$5.00 -> $1.00	N/A
12/16/2015	WallachBeth Capital	Downgrade	Buy -> Hold		N/A
12/12/2015	Bank of America Corp	Reiterated Rating	Sell		N/A
12/4/2015	Wells Fargo & Co	Downgrade	Outperform -> Market Perform		N/A

(Data available from 5/25/2015 forward)

Earnings History for Orexigen Therapeutics (NASDAQ:OREX)

Earnings by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Earnings History by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/9/2017	Q1 2017	($2.60)	($4.67)	$20.00 million	$19.10 million	View	Listen
11/3/2016	Q316	($2.24)	$1.12	$8.17 million	$7.00 million	View	N/A
8/4/2016	Q216	($1.47)	($1.73)	$6.88 million	$7.79 million	View	Listen
5/4/2016	Q116	($0.17)	($0.15)	$7.78 million	$5.00 million	View	Listen
2/26/2016	Q415	($0.08)	($0.12)	$14.07 million	$4.90 million	View	Listen
11/5/2015	Q315	($0.16)	($0.09)	$12.17 million	$10.00 million	View	Listen
8/6/2015	Q215	($0.17)	($0.18)	$4.92 million	$5.20 million	View	Listen
5/8/2015	Q115	($0.16)	($0.14)	$7.28 million	$4.36 million	View	Listen
11/10/2014	Q3	($0.13)	$0.09	$8.93 million	$30.90 million	View	Listen
8/7/2014	Q2	($0.21)	($0.21)	$51.80 million	$0.86 million	View	Listen
5/8/2014	Q1	($0.20)	($0.23)	$0.93 million	$0.86 million	View	Listen
3/12/2014	Q4	($0.19)	($0.21)	$900.00 million	$857.00 million	View	Listen
11/12/2013	Q3	($0.18)	($0.19)	$0.80 million	$0.86 million	View	Listen
8/6/2013	Q2 2013	($0.19)	($0.19)	$0.90 million		View	Listen
3/13/2013	Q4 2012	($0.44)	($0.41)	$0.91 million	$0.86 million	View	Listen
11/7/2012	Q312	($0.30)	($0.44)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Orexigen Therapeutics (NASDAQ:OREX)

Current Year EPS Consensus Estimate: $-8.55 EPS
Next Year EPS Consensus Estimate: $-5.14 EPS

Dividend History for Orexigen Therapeutics (NASDAQ:OREX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Orexigen Therapeutics (NASDAQ:OREX)

Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 49.65%

Institutional Ownership by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Insider Trades by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/19/2016	Stephen A. Moglia	VP	Sell	800	$1.96	$1,568.00
12/2/2014	Heather D Turner	SVP	Sell	22,643	$6.00	$135,858.00
11/25/2014	Heather D Turner	SVP	Sell	31,388	$5.83	$182,992.04
11/18/2014	Louis C Bock	Director	Buy	1,325	$5.58	$7,393.50
11/12/2014	Louis C Bock	Director	Buy	27,052	$5.57	$150,679.64
9/22/2014	Heather D Turner	VP	Sell	300,000	$4.47	$1,341,000.00
9/15/2014	Joseph P Hagan	VP	Buy	5,000	$4.69	$23,450.00
9/15/2014	Michael Narachi	CEO	Buy	50,000	$4.78	$239,000.00
7/31/2013	Joseph P Hagan	Insider	Sell	12,000	$7.80	$93,600.00
7/26/2013	Joseph P Hagan	Insider	Sell	10,000	$7.40	$74,000.00
7/25/2013	Preston Klassen	SVP	Sell	71,229	$7.16	$509,999.64
5/28/2013	Joseph P Hagan	Insider	Sell	28,000	$7.00	$196,000.00
5/28/2013	Preston Klassen	SVP	Sell	28,771	$7.21	$207,438.91
1/15/2013	Mark D Booth	Insider	Sell	22,315	$6.67	$148,841.05

(Data available from 1/1/2013 forward)

Headline Trends for Orexigen Therapeutics (NASDAQ:OREX) Latest Headlines for Orexigen Therapeutics (NASDAQ:OREX)

Source:

Date	Headline
	Orexigen Therapeutics (OREX) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow seekingalpha.com - May 22 at 6:16 PM
	Orexigen Announces Activities at European Congress on Obesity 2017 finance.yahoo.com - May 16 at 6:47 PM
	-$2.40 Earnings Per Share Expected for Orexigen Therapeutics, Inc. (OREX) This Quarter www.americanbankingnews.com - May 16 at 4:04 PM
	Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 - PR Newswire (press release) www.prnewswire.com - May 11 at 7:32 PM
	Edited Transcript of OREX earnings conference call or presentation 9-May-17 9:00pm GMT finance.yahoo.com - May 11 at 12:18 AM
	Orexigen Therapeutics, Inc. (OREX) Announces Quarterly Earnings Results, Misses Expectations By $2.07 EPS www.americanbankingnews.com - May 10 at 7:40 PM
	Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y finance.yahoo.com - May 10 at 11:49 AM
	BRIEF-Orexigen Therapeutics reports Q1 loss per share $4.67 www.reuters.com - May 9 at 6:40 PM
	Orexigen Therapeutics, Inc. 2017 Q1 - Results - Earnings Call Slides seekingalpha.com - May 9 at 6:40 PM
	Investor Network: Orexigen Therapeutics, Inc. to Host Earnings Call finance.yahoo.com - May 9 at 6:40 PM
	Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 finance.yahoo.com - May 9 at 6:40 PM
	Orexigen reports 1Q loss marketbeat.com - May 9 at 5:21 PM
	Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch - PR Newswire (press release) www.prnewswire.com - May 5 at 12:15 AM
	Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba® - Yahoo Finance finance.yahoo.com - May 3 at 7:59 PM
	Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcare Conference finance.yahoo.com - May 3 at 7:59 PM
	Orexigen Therapeutics (OREX) Earns Daily Media Sentiment Score of -0.11 www.americanbankingnews.com - May 3 at 9:44 AM
	Exclusive: Orexigen Therapeutics Execs Talk Contrave And The Stock's Roller-Coaster Ride - Benzinga www.benzinga.com - May 2 at 4:51 PM
	Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for ... - PR Newswire (press release) www.prnewswire.com - May 2 at 4:51 PM
	ETFs with exposure to Orexigen Therapeutics, Inc. : May 2, 2017 finance.yahoo.com - May 2 at 4:51 PM
	Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries finance.yahoo.com - May 2 at 11:10 AM
	Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba® finance.yahoo.com - May 2 at 11:10 AM
	Today's Research Reports on Stocks to Watch: GrubHub and Orexigen Therapeutics - Yahoo Finance finance.yahoo.com - April 28 at 8:36 AM
	Today's Research Reports on Stocks to Watch: GrubHub and Orexigen Therapeutics finance.yahoo.com - April 28 at 8:36 AM
	Research Reports Initiation on Drug Makers Stocks -- Depomed, Pernix Therapeutics, Orexigen Therapeutics, and ... - PR Newswire (press release) www.prnewswire.com - April 28 at 12:33 AM
	Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada - PR Newswire (press release) www.prnewswire.com - April 28 at 12:33 AM
	Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on … finance.yahoo.com - April 26 at 6:12 PM
	Orexigen Therapeutics (OREX) Receiving Somewhat Negative Media Coverage, Study Finds www.americanbankingnews.com - April 26 at 3:02 PM
	Brokerages Expect Orexigen Therapeutics, Inc. (OREX) to Announce -$2.60 Earnings Per Share www.americanbankingnews.com - April 26 at 12:03 AM
	Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on May 9, 2017 finance.yahoo.com - April 25 at 6:15 PM
	Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada finance.yahoo.com - April 25 at 9:46 AM
	Orexigen Therapeutics (OREX) Receives News Sentiment Rating of -0.20 www.americanbankingnews.com - April 21 at 12:53 PM
	ETFs with exposure to Orexigen Therapeutics, Inc. : April 17, 2017 finance.yahoo.com - April 17 at 6:13 PM
	Orexigen Therapeutics (OREX) Receiving Somewhat Favorable Media Coverage, Analysis Shows www.americanbankingnews.com - April 13 at 2:20 PM
	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Potential … finance.yahoo.com - April 7 at 11:44 AM
	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors finance.yahoo.com - April 7 at 11:44 AM
	ETFs with exposure to Orexigen Therapeutics, Inc. : April 5, 2017 finance.yahoo.com - April 7 at 11:44 AM
	Orexigen Therapeutics, Inc. (OREX) Sees Large Decrease in Short Interest www.americanbankingnews.com - April 5 at 8:27 AM
	OREXIGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report us.rd.yahoo.com - March 30 at 7:20 PM
	OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and biz.yahoo.com - March 30 at 7:20 PM
	Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 - PR Newswire (press release) www.prnewswire.com - March 30 at 5:47 AM
	Earnings Reaction History: Orexigen Therapeutics, Inc., 75.0% Follow-Through Indicator, 10.3% Sensitive - Nasdaq www.nasdaq.com - March 30 at 5:47 AM
	Pre-Open Stock Movers 03/29: (EXAR) (ATHX) (VRTX) Higher; (ALQA) (PTX) (SKX) (FFIV) Lower (more...) www.streetinsider.com - March 29 at 7:45 PM
	Edited Transcript of OREX earnings conference call or presentation 28-Mar-17 9:00pm GMT finance.yahoo.com - March 29 at 9:16 AM
	After-Hours Stock Movers 03/28: (ATHX) (RH) (VRNT) Higher; (ALQA) (PTX) (AST) Lower (more...) www.streetinsider.com - March 28 at 6:52 PM
	BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Bruno Farmaceutici S.p.A. for Mysimba in Italy www.reuters.com - March 28 at 6:52 PM
	Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2 … finance.yahoo.com - March 28 at 6:52 PM
	Orexigen Therapeutics, Inc. 2016 Q4 - Results - Earnings Call Slides seekingalpha.com - March 28 at 6:52 PM
	Orexigen Inks Commercialization Deal for Contrave, Stock Up us.rd.yahoo.com - March 28 at 6:52 PM
	Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 us.rd.yahoo.com - March 28 at 6:52 PM
	OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a us.rd.yahoo.com - March 28 at 6:52 PM